	Hovione is investing in specialized formulation capabilities, beginning with the acquisition of a formulation facility adjacent to the current process chemistry and particle engineering facility in Loures, Portugal, the company announced on Oct. 19, 2015. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms.

	The facility will be engineered for highly potent APIs and moisture-sensitive compounds and will have dedicated rooms to allow for concurrent manufacture of these products. The facility will be capable of preparing a wide range of materials suitable for clinical trials and commercial batches meeting global regulatory requirements.

API Synthesis and Manufacturing, Small Molecule

Development

Dosage Forms

Formulation

Highly Potent Drugs

Ingredients

PharmTech News

Small-Molecule APIs

Solid/Semi-Solid Dosage

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015

Hovione is investing in specialized formulation capabilities, beginning with the acquisition of a formulation facility adjacent to the current process chemistry and particle engineering facility in Loures, Portugal, the company announced on Oct. 19, 2015. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms.

Hovione Expands Formulation Capabilities